A carregar...
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
During the last 10 years, the multikinase inhibitor sorafenib has emerged as the only systemic treatment for unresectable hepatocellular carcinoma (HCC). More recently, data from the Phase III REFLECT trial showed that another multikinase inhibitor, namely, lenvatinib, was non-inferior to sorafenib...
Na minha lista:
| Publicado no: | J Hepatocell Carcinoma |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6362912/ https://ncbi.nlm.nih.gov/pubmed/30775342 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S168953 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|